Your browser doesn't support javascript.
loading
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
McQuilten, Zoe K; Busija, Ljoudmila; Seymour, John F; Stanworth, Simon; Wood, Erica M; Kenealy, Melita; Weinkove, Robert.
Affiliation
  • McQuilten ZK; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
  • Busija L; Department of Haematology, Monash Health, Melbourne, Australia.
  • Seymour JF; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
  • Stanworth S; Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia.
  • Wood EM; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Kenealy M; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Weinkove R; Clinical Department, NHS Blood and Transplant, Oxford, UK.
Leuk Lymphoma ; 63(3): 676-683, 2022 03.
Article in En | MEDLINE | ID: mdl-34915809
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Aged / Humans Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Aged / Humans Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Australia